UCB Spotlights Bimekizumab And Other Later-Stage R&D Projects
Executive Summary
Belgium-headquartered UCB has a group of antibody-based products in mid to late-stage clinical studies which will be competing in the dermatology/immune disorders marketplace in the next few years.
You may also be interested in...
Psoriasis Drugs Poised For The Q2 Spotlight
With Celgene's psoriasis pill Otezla for sale and AbbVie in the midst of launching a new competitor to blockbuster brands like Novartis' Cosentyx and J&J's Tremfya, investors will be focused on the category as drug makers report second quarter financials.
‘Disappointed’ UCB And Amgen Will Appeal CHMP’s Negative Evenity Decision
The EMA’s CHMP cited concerns over cardiovascular side effects as the reason why it took a negative stance on Evenity’s use in the EU for treating severe osteoporosis.
Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray
The latest drug development news and highlights from our US FDA Performance Tracker.